NKTR Stock Overview
A biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Nektar Therapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.01 |
| 52 Week High | US$1.93 |
| 52 Week Low | US$0.42 |
| Beta | 0.61 |
| 11 Month Change | -29.86% |
| 3 Month Change | -25.19% |
| 1 Year Change | 104.45% |
| 33 Year Change | -91.31% |
| 5 Year Change | -95.08% |
| Change since IPO | -73.07% |
Recent News & Updates
Recent updates
Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking
Oct 18
Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding
Jun 19There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise
Feb 15Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry
Dec 31Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?
Nov 06Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?
Apr 24Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely
Jan 24Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?
Aug 19Nektar: Time To Abandon Ship
Jul 17Nektar promotes internal executive to CFO role
Jul 01We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully
May 11After A High-Profile Failure In Melanoma, Nektar Therapeutics' Value Shifts To Its Early-Stage Pipeline
Apr 04Shareholder Returns
| NKTR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -13.7% | -3.8% | -1.0% |
| 1Y | 104.5% | 9.8% | 30.3% |
Return vs Industry: NKTR exceeded the US Pharmaceuticals industry which returned 9.8% over the past year.
Return vs Market: NKTR exceeded the US Market which returned 30.3% over the past year.
Price Volatility
| NKTR volatility | |
|---|---|
| NKTR Average Weekly Movement | 10.0% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NKTR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NKTR's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 137 | Howard Robin | www.nektar.com |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer. The company serves its clients in the United States and internationally.
Nektar Therapeutics Fundamentals Summary
| NKTR fundamental statistics | |
|---|---|
| Market cap | US$184.46m |
| Earnings (TTM) | -US$168.30m |
| Revenue (TTM) | US$93.14m |
2.0x
P/S Ratio-1.1x
P/E RatioIs NKTR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NKTR income statement (TTM) | |
|---|---|
| Revenue | US$93.14m |
| Cost of Revenue | US$29.99m |
| Gross Profit | US$63.15m |
| Other Expenses | US$231.45m |
| Earnings | -US$168.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.91 |
| Gross Margin | 67.80% |
| Net Profit Margin | -180.70% |
| Debt/Equity Ratio | 200.1% |
How did NKTR perform over the long term?
See historical performance and comparison